PMID- 22676966
OWN - NLM
STAT- MEDLINE
DCOM- 20130821
LR  - 20220330
IS  - 1469-5111 (Electronic)
IS  - 1461-1457 (Print)
IS  - 1461-1457 (Linking)
VI  - 16
IP  - 2
DP  - 2013 Mar
TI  - Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity 
      in major depressive disorder.
PG  - 301-11
LID - 10.1017/S1461145712000545 [doi]
AB  - The N-methyl-d-aspartate (NMDA) receptor antagonist ketamine has rapid 
      antidepressant effects in treatment-resistant major depressive disorder (MDD). In 
      rats, ketamine selectively increased electroencephalogram (EEG) slow wave 
      activity (SWA) during non-rapid eye movement (REM) sleep and altered central 
      brain-derived neurotrophic factor (BDNF) expression. Taken together, these 
      findings suggest that higher SWA and BDNF levels may respectively represent 
      electrophysiological and molecular correlates of mood improvement following 
      ketamine treatment. This study investigated the acute effects of a single 
      ketamine infusion on depressive symptoms, EEG SWA, individual slow wave 
      parameters (surrogate markers of central synaptic plasticity) and plasma BDNF (a 
      peripheral marker of plasticity) in 30 patients with treatment-resistant MDD. 
      Montgomery-Asberg Depression Rating Scale scores rapidly decreased following 
      ketamine. Compared to baseline, BDNF levels and early sleep SWA (during the first 
      non-REM episode) increased after ketamine. The occurrence of high amplitude waves 
      increased during early sleep, accompanied by an increase in slow wave slope, 
      consistent with increased synaptic strength. Changes in BDNF levels were 
      proportional to changes in EEG parameters. Intriguingly, this link was present 
      only in patients who responded to ketamine treatment, suggesting that enhanced 
      synaptic plasticity - as reflected by increased SWA, individual slow wave 
      parameters and plasma BDNF - is part of the physiological mechanism underlying 
      the rapid antidepressant effects of NMDA antagonists. Further studies are 
      required to confirm the link found here between behavioural and synaptic changes, 
      as well as to test the reliability of these central and peripheral biomarkers of 
      rapid antidepressant response.
FAU - Duncan, Wallace C
AU  - Duncan WC
AD  - Experimental Therapeutics and Pathophysiology Branch, Intramural Research 
      Program, National Institute of Mental Health, National Institutes of Health, 
      Bethesda, MD, USA.
FAU - Sarasso, Simone
AU  - Sarasso S
FAU - Ferrarelli, Fabio
AU  - Ferrarelli F
FAU - Selter, Jessica
AU  - Selter J
FAU - Riedner, Brady A
AU  - Riedner BA
FAU - Hejazi, Nadia S
AU  - Hejazi NS
FAU - Yuan, Peixiong
AU  - Yuan P
FAU - Brutsche, Nancy
AU  - Brutsche N
FAU - Manji, Husseini K
AU  - Manji HK
FAU - Tononi, Giulio
AU  - Tononi G
FAU - Zarate, Carlos A
AU  - Zarate CA
LA  - eng
GR  - ZIA MH002857-07/Intramural NIH HHS/United States
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20120607
PL  - England
TA  - Int J Neuropsychopharmacol
JT  - The international journal of neuropsychopharmacology
JID - 9815893
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Excitatory Amino Acid Antagonists)
RN  - 690G0D6V8H (Ketamine)
RN  - 7LJ087RS6F (Riluzole)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Brain Waves/*drug effects
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Depressive Disorder, Major/blood/*drug therapy
MH  - Electroencephalography
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Excitatory Amino Acid Antagonists/*therapeutic use
MH  - Female
MH  - Humans
MH  - Ketamine/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Psychiatric Status Rating Scales
MH  - Riluzole/therapeutic use
MH  - Single-Blind Method
MH  - Sleep Stages/*drug effects
MH  - Statistics as Topic
MH  - Time Factors
PMC - PMC3510337
MID - NIHMS402046
EDAT- 2012/06/09 06:00
MHDA- 2013/08/22 06:00
PMCR- 2014/03/01
CRDT- 2012/06/09 06:00
PHST- 2012/06/09 06:00 [entrez]
PHST- 2012/06/09 06:00 [pubmed]
PHST- 2013/08/22 06:00 [medline]
PHST- 2014/03/01 00:00 [pmc-release]
AID - S1461145712000545 [pii]
AID - 10.1017/S1461145712000545 [doi]
PST - ppublish
SO  - Int J Neuropsychopharmacol. 2013 Mar;16(2):301-11. doi: 
      10.1017/S1461145712000545. Epub 2012 Jun 7.